In­cyte stops PhI­II tri­al for PI3K in­hibitor af­ter pri­ma­ry end­point fail­ure

In­cyte has called it quits on a Phase III study for its oral PI3K in­hibitor, parsaclis­ib, a year af­ter with­draw­ing its ac­cel­er­at­ed ap­proval pitch for a dif­fer­ent in­di­ca­tion.

The study was look­ing at parsaclis­ib plus rux­oli­tinib ver­sus a place­bo plus rux­oli­tinib in myelofi­bro­sis (MF) pa­tients 18 years and old­er who had an “in­ad­e­quate” re­sponse to rux­oli­tinib monother­a­py. MF is a rare, chron­ic blood can­cer that af­fects the bone mar­row and the pro­duc­tion of blood cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER